INVOcell Fertility Treatment Now Offered at Family Beginnings in Indianapolis
INDIANAPOLIS and MEDFORD, Mass., March 6, 2018 — INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, and Family Beginnings of Indianapolis, are pleased to announce that they are now offering the INVOcell device and procedure to its patients. Family Beginnings is the first center in Indiana to begin offering the new revolutionary device and procedure.
INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman’s body, in vivo. The INVO Solution allows women to incubate their own gametes, providing a psychological benefit while reducing the risk of wrong embryo transfer. Utilizing a mild stimulation protocol, it decreases the number of oocytes required, which may reduce the risk of severe ovarian hyperstimulation (OHSS), reduce the risk of multiple births, and/or reduce the need for embryo cryopreservation and storage. As a lower cost option to traditional IVF, INVOcell expands access to patients who may otherwise cannot afford the traditional method or would prefer a more natural, cultural, or religious appropriate choice.
Dr. James G. Donahue, M.D., HCLD at Family Beginnings, commented, “Family Beginnings, PC, and Drs. James Donahueand Leo Bonaventura are pleased to announce that the first INVOcell patient in our state got pregnant with twins and is now doing well in the second trimester. Over the past 3 months we have had multiple pregnancies and we are convinced that the quality of the embryos is equal to if not greater than those cultured in the laboratory incubator. The patients feel empowered to be part pf the process, and it seems like embryos grow better in the body for most of the patients we have treated. The INVOcell fulfills the ‘Triple Aim’ in Healthcare: Improved patient experience, improved infertility healthcare, and reduced costs. Please see our web site: www.invocellindiana.com.”
Family Beginnings, PC has helped thousands of patients in Central Indiana over the past 9 years. Dr. Donahue is personally involved with all aspects of his patients’ care. Family Beginnings strives to provide the most advanced infertility care available, offering the full range of therapies in an appropriate fashion to minimize patient cost and stress while maximizing pregnancy outcome. They understand that each couple is unique in their medical history and personal desires and tailor their treatments to meet those needs. Family Beginnings physicians are always available to address their patient’s concerns.
“I am pleased that Dr. Donahue and his team at Family Beginnings have become the first center in the state of Indianato begin offering the INVOcell solution,” said Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience. “INVOcell can offer patients an attractive alternative to costly IVF procedures and ineffective IUI procedures. This unique balance of equivalent efficacy to traditional IVF at about half the price will allow Dr. Donahue to assist more patients throughout Indiana in the coming years to become pregnant and share in the joy of parenthood.”
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
INVO Bioscience, Inc.
Kathleen Karloff, CEO
978-878-9505 ext. 504
Dr. James Donahue